

W Health Ventures announces initial close of Fund II at Rs 550Cr to launch and scale healthcare companies

13 February 2026 | News

W Health Ventures has begun deploying capital from its second fund



W Health Ventures has announced the initial close of Fund II at Rs 550 crore, aiming toward a target of Rs 630 crore. The firm will continue to double down on its company creation model by building and scaling healthcare companies from scratch in India and across the US-India corridor.

W Health Ventures' Fund I companies include Nivaan (chronic pain), BeatO (diabetes), ElevateNow (obesity), BabyMD (paediatrics), and Mylo (parenting) in India, along with cross-border companies like Wysa (AI mental health services) and Reveal HealthTech (AI transformation services). All Fund I companies have raised external growth capital.

With Fund II, W Health Ventures expects to take larger, bolder bets on company creation. The firm plans to build and scale 8 to 10 new companies over the next four years, investing Rs 30 to 50 crore in each incubation.

W Health Ventures has begun deploying capital from its second fund. Everhope Oncology, the first company from Fund II, is a national oncology platform founded with Narayana Health to reimagine cancer care in India. The company is integrating global advances in oncology into coordinated, patient-centered care from diagnosis through recovery. A stealth incubation is helping psychiatry clinics in the US to launch and scale advanced treatments for patients with treatment-resistant depression. The fund is currently exploring opportunities in spaces such as longevity and modern preventive health, geriatrics, and chronic pain management.